The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis

BACKGROUND: Recently, several high-quality clinical randomized controlled trials (RCTs) have identified that cyclin-dependent kinases (CDKs) 4/6 inhibitors obtained a great safety and efficacy, which can be consequently applied as a combination therapy with letrozole or fulvestrant for women who had...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Wu, Li, Zhian, Wang, Caiyun, Ruan, GuoDong, Chen, LuPing, Tu, Chuanjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976281/
https://www.ncbi.nlm.nih.gov/pubmed/29768351
http://dx.doi.org/10.1097/MD.0000000000010746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976281/
https://www.ncbi.nlm.nih.gov/pubmed/29768351
http://dx.doi.org/10.1097/MD.0000000000010746

Ejemplares similares